Literature DB >> 8164820

Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging.

B S Oken1, S S Kishiyama, J A Kaye, D B Howieson.   

Abstract

OBJECTIVE: To evaluate attention deficit in Alzheimer's disease (AD) and its relationship to attention deficits associated with aging and with medications altering alertness.
METHODS: Ten patients with probable AD, 10 healthy old controls, and 15 young controls performed a covert orienting of spatial attention task. Young controls performed the task an additional time after ingestion of diphenhydramine 1 mg/kg. Reaction times were obtained following valid, neutral, and invalid cues.
RESULTS: In all groups, the reaction times were shortest for the validly cued stimuli and longest for the invalidly cued stimuli. Additionally, the AD patients performed disproportionately worse following the invalid cue than did the control groups. Young controls given diphenhydramine had decreased subjective alertness, performed worse than they did before drug but better than the old controls or AD patients, and had no disproportionate impairment with the invalid cue.
CONCLUSIONS: AD patients have disproportionate problems shifting spatial attention compared with age-matched controls. Impaired attentional performance in AD cannot be simulated in young subjects by ingestion of a combined antihistamine/anticholinergic agent at a dose sufficient to produce significant changes in alertness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164820     DOI: 10.1212/wnl.44.4.657

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention.

Authors:  J Fadel; J A Burk
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

Review 2.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 3.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  Methylphenidate Treatment for Patients With Posterior Cortical Atrophy.

Authors:  Mario F Mendez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2018-04-24       Impact factor: 2.198

5.  Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life.

Authors:  Barry S Oken; Daniel Zajdel; Shirley Kishiyama; Kristin Flegal; Cathleen Dehen; Mitchell Haas; Dale F Kraemer; Julie Lawrence; Joanne Leyva
Journal:  Altern Ther Health Med       Date:  2006 Jan-Feb       Impact factor: 1.305

Review 6.  The apolipoprotein E gene, attention, and brain function.

Authors:  Raja Parasuraman; Pamela M Greenwood; Trey Sunderland
Journal:  Neuropsychology       Date:  2002-04       Impact factor: 3.295

Review 7.  Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia.

Authors:  Martin Taylor-Rowan; Olga Kraia; Christina Kolliopoulou; Anna H Noel-Storr; Ahmed A Alharthi; Amanda J Cross; Carrie Stewart; Phyo K Myint; Jenny McCleery; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

Review 8.  [Visual search in healthy persons and Alzheimer's patients: relating cognitive function to clinical practice].

Authors:  A Rösler; N Müller
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

9.  Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats.

Authors:  Coleman B Calva; Habiba Fayyaz; Jim R Fadel
Journal:  Front Aging Neurosci       Date:  2020-01-22       Impact factor: 5.750

10.  Functional neural correlates of attentional deficits in amnestic mild cognitive impairment.

Authors:  Nicholas T Van Dam; Mary Sano; Effie M Mitsis; Hillel T Grossman; Xiaosi Gu; Yunsoo Park; Patrick R Hof; Jin Fan
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.